Literature DB >> 2509529

Congestive heart failure induced by six of the newer antiarrhythmic drugs.

S Ravid1, P J Podrid, S Lampert, B Lown.   

Abstract

The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests. The incidence rate ranged from 0.7% with lorcainide to 4.7% with propafenone. Congestive heart failure was present in 167 patients (41%) who underwent 491 drug trials. Congestive failure was induced in 15 (9%) of these 167 patients and involved 19 (3.9%) of the 491 tests. Left ventricular ejection fraction was 20 +/- 8% in patients who developed congestive failure, in contrast to 39 +/- 19% in those who did not (p less than 0.001). It is concluded that each of the six antiarrhythmic drugs examined has the potential to aggravate congestive heart failure in patients with reduced left ventricular ejection fraction or a history of congestive heart failure, but the incidence rate is low and its occurrence unpredictable.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509529     DOI: 10.1016/0735-1097(89)90436-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Arrhythmias in Heart Failure.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

Review 2.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 3.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 4.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study.

Authors:  A Bayés de Luna; J Guindo; J Borja; M Roman; C Madoery
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

6.  Atrioventricular nodal ablation versus antiarrhythmic drugs after permanent pacemaker implantation for bradycardia-tachycardia syndrome.

Authors:  Yasutsugu Nagamoto; Tomohito Inage; Teruhisa Yoshida; Tomohiro Takeuchi; Takeki Gondo; Yujiro Fukuda; Eiichi Takii; Kenta Murotani; Tsutomu Imaizumi
Journal:  Heart Vessels       Date:  2011-04-20       Impact factor: 2.037

7.  Cardiac electrophysiologic and antiarrhythmic actions of a pavine alkaloid derivative, O-methyl-neocaryachine, in rat heart.

Authors:  Gwo-Jyh Chang; Ming-Jai Su; Li-Man Hung; Shoei-Sheng Lee
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 8.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 9.  Guidelines for the use of propafenone in treating supraventricular arrhythmias.

Authors:  A G Kishore; A J Camm
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.